ARS Pharmaceuticals, Inc. — Director's Dealing 2024

Dec 5, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-12-02

Reporting Person: Karas Eric (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-02	Common Stock	M	3717	$1.50	Acquired	9410	Direct
2024-12-02	Common Stock	S	3717	$14.1139	Disposed	5693	Direct
2024-12-04	Common Stock	M	6283	$1.50	Acquired	11976	Direct
2024-12-04	Common Stock	S	6283	$14	Disposed	5693	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-02	Stock Option (Right to Buy)	$1.50	M	3717	Disposed	2032-05-23	Common Stock (3717)	Direct
2024-12-04	Stock Option (Right to Buy)	$1.50	M	6283	Disposed	2032-05-23	Common Stock (6283)	Direct

Footnotes

F1: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.

F2: The weighted average sale price for the transaction reported was $14.1139, and the range of prices were between $14.00 and $14.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each
separate price will be provided.

F3: Immediately exercisable.